急性骨髓性白血病市场 - 全球产业规模、份额、趋势、机会和预测，按化疗、地区和竞争细分，2019-2029F

2023年全球急性骨髓性白血病市场价值为7.5亿美元，预计在预测期内将出现令人印象深刻的成长，到2029年复合年增长率为8.70%。

市场概况
预测期	2025-2029
2023 年市场规模	7.5亿美元
2029 年市场规模	12.2亿美元
2024-2029 年复合年增长率	8. 70%
成长最快的细分市场	荷尔蒙疗法
最大的市场	北美洲

急性骨髓性白血病(AML) 是一种影响骨髓和血液的癌症。它的特征是异常骨髓细胞的快速生长，这些细胞是负责抵抗感染和携带氧气的未成熟白血球。在 AML 中，这些异常细胞无法正常成熟，并排挤骨髓中的健康细胞，导致正常血球生成减少。这可能会导致各种症状和併发症。 AML 可引起一系列症状，包括疲劳、虚弱、贫血（红血球数低）、感染易感性增加、容易出血或瘀伤（由于血小板数量低）、发烧和体重减轻。有些患者还可能会出现骨痛。新的和改进的疗法（包括标靶疗法和免疫疗法）的开发扩大了 AML 患者的治疗选择。这些进步提供了更有效和个人化的治疗方法。

AML 领域持续的研究和开发工作导致了新的治疗标靶和治疗策略的发现。这项创新吸引了投资并推动市场向前发展。分子诊断学的进步使得能够识别与 AML 相关的特定基因突变和标记。这为个人化治疗方法铺平了道路，增加了对标靶治疗的需求。监管机构批准用于治疗 AML 的新疗法透过扩大可用的治疗选择和改善患者的治疗效果来促进市场成长。对 AML 症状和早期诊断重要性的认识提高，导致更多患者在早期阶段寻求治疗，从而可能改善结果并推动对治疗的需求。

主要市场驱动因素

治疗方案的进步

临床研究与创新

意识和早期诊断

主要市场挑战

缺乏患者分层的生物标记

干细胞捐赠者的供应有限

主要市场趋势

患者的可近性和负担能力

细分市场洞察

化疗见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：COVID-19 对全球急性骨髓性白血病市场的影响

第 5 章：客户之声

第 6 章：全球急性骨髓性白血病市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过化疗（阿糖胞苷、蒽环类药物、烷化剂、抗代谢药、酪胺酸激酶抑制剂、荷尔蒙治疗和其他化疗）
  • 按地区
  • 按公司划分 (2023)
• 市场地图

第 7 章：亚太地区急性骨髓性白血病市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过化疗
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 8 章：欧洲急性骨髓性白血病市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过化疗
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 9 章：北美急性骨髓性白血病市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过化疗
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 10 章：南美洲急性骨髓性白血病市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过化疗
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲急性骨髓性白血病市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过化疗
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：市场动态

• 司机
• 挑战

第 13 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 14 章：全球急性骨髓性白血病市场：SWOT 分析

第 15 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第 16 章：大环境分析

第17章：竞争格局

• Bristol-Myers Squibb Company (Celgene Corporation)
• Novartis AG
• Genmab AS
• Otsuka Holdings Co. Ltd
• Sanofi-Aventis (Genzyme Corporation)
• Teva Pharmaceutical (Cephalon Inc.)
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Sunesis Pharmaceuticals Inc.
• Astellas Pharma
• Oncolyze Inc.
• Syndax Pharmaceuticals Inc.
• AbbVie Inc.
• Amgen Inc.
• Agios Pharmaceuticals Inc.

第 18 章：策略建议

第19章调查会社について・免责事项

Global Acute Myeloid Leukemia Market was valued at USD 0.75 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.70% through 2029.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 0.75 Billion
Market Size 2029	USD 1.22 Billion
CAGR 2024-2029	8. 70%
Fastest Growing Segment	Hormonal therapy
Largest Market	North America

Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. It is characterized by the rapid growth of abnormal myeloid cells, which are immature white blood cells responsible for fighting infections and carrying oxygen. In AML, these abnormal cells do not mature properly and crowd out healthy cells in the bone marrow, leading to a decrease in the production of normal blood cells. This can result in a variety of symptoms and complications. AML can cause a range of symptoms, including fatigue, weakness, anemia (low red blood cell count), increased susceptibility to infections, bleeding or bruising easily (due to low platelet count), fever, and weight loss. Some patients may also experience bone pain. The development of new and improved therapies, including targeted therapies and immunotherapies, has expanded the treatment options available for AML patients. These advancements provide more effective and personalized treatment approaches.

Ongoing research and development efforts in the field of AML have led to the discovery of novel therapeutic targets and treatment strategies. This innovation attracts investment and drives the market forward. Advances in molecular diagnostics have enabled the identification of specific genetic mutations and markers associated with AML. This has paved the way for personalized treatment approaches, increasing the demand for targeted therapies. Regulatory agencies approving new therapies for AML treatment contribute to market growth by expanding the available treatment options and improving patient outcomes. Improved awareness of AML symptoms and the importance of early diagnosis has led to more patients seeking treatment at an earlier stage, potentially improving outcomes, and driving demand for therapies.

Key Market Drivers

Advancements in Treatment Options

The development of targeted therapies that focus on specific genetic mutations or molecular markers associated with AML has been a breakthrough. Drugs like "FLT3 inhibitors" and "IDH inhibitors" target specific mutations in leukemia cells, leading to more effective and tailored treatments. Immunotherapies, including monoclonal antibodies and checkpoint inhibitors, are being explored for their potential in AML treatment. These therapies harness the body's immune system to recognize and attack leukemia cells. The rise of precision medicine involves tailoring treatment based on a patient's unique genetic and molecular profile. This approach allows for personalized treatment strategies that have the potential to be more effective and less toxic.

Epigenetic changes play a significant role in AML development. Drugs that target these changes, such as "DNMT inhibitors" and "HDAC inhibitors," are being studied as potential treatments. Venetoclax, an inhibitor of BCL-2, has shown promise in combination with other therapies, particularly in older adults or those with certain genetic mutations. Advances in detecting very low levels of leukemia cells, known as MRD, have allowed for more accurate assessment of treatment response and adjustment of treatment strategies accordingly. Techniques for stem cell transplantation have improved, expanding the eligibility criteria, and reducing complications associated with the procedure. Researchers are investigating various combinations of chemotherapy, targeted therapies, and immunotherapies to enhance treatment efficacy while minimizing side effects. Advances in supportive care, such as anti-nausea medications and infection prevention strategies, have improved patients' ability to tolerate intensive treatments. This factor will help in the development of the global acute myeloid leukemia market.

Clinical Research and Innovation

Clinical research and innovative developments contribute to the evolution of treatment approaches, the introduction of new therapies, and improved patient outcomes. Clinical research leads to the discovery and development of new therapies, including targeted agents, immunotherapies, and other innovative treatment modalities. These novel therapies create new options for patients who may have exhausted traditional treatments. Through clinical trials, researchers can assess the efficacy of new treatments in comparison to existing therapies. Positive outcomes from these trials lead to increased adoption of the new treatments by healthcare providers, driving demand. Clinical research identifies genetic mutations and biomarkers associated with AML. This information enables personalized treatment approaches that target the specific characteristics of a patient's disease, increasing the demand for tailored therapies. Innovations in treatment contribute to improved survival rates among AML patients. Positive outcomes from clinical trials and real-world data encourage healthcare providers to adopt these treatments, increasing patient demand.

Robust clinical research attracts investments from pharmaceutical companies, biotech firms, and venture capitalists. The potential for innovative therapies in AML encourages funding and resources to be directed toward the development of these treatments. The participation of AML patients in clinical trials provides access to cutting-edge treatments that might not be available through standard care. This participation fosters patient demand for advanced therapies. Positive clinical trial outcomes often lead to regulatory approvals by health authorities such as the FDA and EMA. These approvals legitimize new therapies and encourage their adoption in clinical practice. Clinical research findings are shared through medical conferences, publications, and educational programs. Healthcare providers learn about new treatment options and are more likely to offer them to their patients. International collaborations among researchers, institutions, and pharmaceutical companies accelerate the pace of innovation. The collective effort contributes to the development of more effective treatments. Patients and advocacy groups are often strong advocates for clinical research and innovative treatments. Their efforts raise awareness, drive demand for research funding, and push for expedited access to promising therapies. This factor will pace up the demand of the global acute myeloid leukemia market.

Awareness and Early Diagnosis

Early diagnosis allows for timely initiation of treatment, which can lead to better treatment outcomes and increased chances of remission. As awareness spreads about the importance of early detection, more patients are likely to seek medical attention promptly. Raising awareness about AML symptoms, risk factors, and the benefits of early diagnosis can lead to a larger patient pool seeking medical evaluation. This, in turn, drives demand for diagnostic tests, treatments, and supportive care services. When AML is diagnosed at an earlier stage, patients may have a lower tumor burden, making treatments more effective. Early treatment can potentially reduce disease progression and the need for more aggressive therapies. Increased awareness may encourage individuals to adopt healthier lifestyles and seek routine check-ups, helping to identify potential risk factors and enabling early intervention to prevent the development of AML.

Heightened awareness empowers patients to recognize symptoms, communicate concerns with healthcare providers, and advocate for appropriate diagnostic tests and treatments. Awareness campaigns, educational programs, and patient advocacy efforts contribute to educating the public, healthcare professionals, and policymakers about AML, its symptoms, and the importance of early diagnosis. Early diagnosis may lead to less advanced disease stages, resulting in shorter hospital stays, fewer complications, and lower healthcare costs. This can drive healthcare systems to invest in early detection and management programs. As awareness increases, funding for research and innovation in AML diagnosis and treatment may also rise, stimulating advancements in diagnostics and therapies. International efforts to promote cancer awareness and early diagnosis contribute to the broader effort to improve cancer care, including AML, on a global scale. In some cases, increased awareness about AML can lead to the establishment of screening programs, allowing for early detection and intervention in high-risk populations. This factor will accelerate the demand of the global acute myeloid leukemia market.

Key Market Challenges

Lack of Biomarkers for Patient Stratification

Biomarkers are crucial indicators that help healthcare professionals predict disease behavior, determine treatment response, and tailor therapies to individual patients. In AML, the absence of reliable biomarkers for accurate patient stratification can impact treatment decisions and outcomes. Biomarkers help guide treatment decisions by identifying patients who are likely to respond to specific therapies. Without effective biomarkers, treatments may be less targeted, potentially leading to suboptimal outcomes. Biomarkers enable the development of targeted and personalized treatment strategies that are more effective and associated with fewer side effects. Biomarkers are essential in the development of new therapies. A lack of biomarkers can hinder the identification of patients who are most likely to benefit from a new drug, leading to challenges in clinical trial design and drug approvals. Biomarkers play a crucial role in patient enrollment and stratification in clinical trials. Without biomarkers, trials may include a heterogeneous patient population, making it challenging to interpret trial results accurately. Lack of biomarkers can lead to more generalized treatment guidelines rather than specific recommendations based on individual patient characteristics. The identification of biomarkers often directs research efforts toward understanding the underlying biology of AML, leading to potential breakthroughs in treatment strategies.

Limited Availability of Stem Cell Donors

Stem cell transplantation, which includes bone marrow and hematopoietic stem cell transplantation, is a potentially curative treatment option for many AML patients. However, finding a compatible donor can be complex and challenging. Stem cell transplantation requires a compatible donor, usually a family member or an unrelated donor with matching tissue types. The chances of finding a suitable donor decrease as the genetic diversity between patients and potential donors increases. AML affects people from diverse ethnic backgrounds, and ethnicity plays a crucial role in finding a compatible donor. Patients from minority groups may face greater difficulty in finding a matched donor due to the underrepresentation of certain ethnicities in donor registries. International registries of potential stem cell donors have been established to improve donor matching. However, these registries still face challenges in achieving a diverse representation of donors from different populations. In cases where a fully matched donor cannot be found, haploidentical transplantation from a partially matched family member is an option. However, this procedure may carry higher risks. Umbilical cord blood contains stem cells and can be used for transplantation. Cord blood banks have been established to provide another source of stem cells, but the quantity of cells in a single unit may not be sufficient for larger patients. AML treatment decisions are time-sensitive, and delays in finding a suitable donor can impact treatment outcomes and patient survival.

Key Market Trends

Patient Access and Affordability

Patient access and affordability are indeed important trends in the Global Acute Myeloid Leukemia (AML) Market. Ensuring that AML patients have access to appropriate treatments and therapies without facing financial hardships is crucial for equitable and effective healthcare delivery. Patient access ensures that all individuals, regardless of their socioeconomic status, can receive timely and appropriate AML treatments. Addressing disparities in access contributes to more equitable healthcare. Efforts to improve patient access often involve expanding the availability of approved treatments, including novel therapies, targeted agents, and innovative treatment modalities. The high costs associated with AML treatment can be a barrier to access. Market trends involve finding ways to make treatments more affordable through pricing strategies, insurance coverage, and patient assistance programs. Government and healthcare regulatory bodies may implement policies to enhance patient access and affordability, such as price controls or reimbursement adjustments for specific treatments. Ensuring that AML treatments are covered by insurance plans, including government-funded programs, can significantly improve patient access and alleviate financial burdens. Pharmaceutical companies and organizations often offer patient assistance programs that provide financial support to eligible patients who may struggle with the cost of treatments.

Segmental Insights

Chemotherapy Insights

In 2023, the Cytarabine segment is witnessing highest growth and is predicted to continue expanding over the coming years. Acute and chronic myelogenous leukaemia (AML and CML), acute lymphocytic leukaemia (ALL), and acute promyelocytic leukaemia (APL) are among the several leukaemia types that can be treated with cytarabine. Along with other lymphoma (cancers found in the lining of the brain and spinal cord), it can treat Hodgkin's lymphoma, meningeal leukaemia, and other forms of lymphoma. Cytarabine is frequently used during chemotherapy because it is useful in treating acute myeloid leukaemia. Cytarabine is frequently used because, according to cancer organisations like Macmillan Cancer Support, it is more effective against acute myeloid leukaemia. As a result, it is anticipated that this sub-segment will account for a sizeable portion of the chemotherapy market.

Regional Insights

The North America region dominated the Global Acute Myeloid Leukemia Market in 2023. This market in this region is anticipated to expand because of the increased incidence of acute myeloid leukaemia cases in the US. For instance, acute myeloid leukaemia is a rare cancer that makes up about 1% of all malignancies, according to the American Society of Clinical Oncology in 2021. In the US, this disease was thought to have affected 20,240 persons of all ages in 2021 (11,230 men and boys and 9,010 women and girls). AML is the second most common kind of leukaemia in both adults and children, with cases primarily affecting adults. Since acute myeloid leukaemia is becoming more common in the US, more people will likely use its treatments, which is predicted to fuel the market's expansion in North America. Rising R&D spending and new product introductions for acute myeloid leukaemia are also anticipated to fuel market expansion in this area.

Due to the expansion of government initiatives to raise public awareness, an increase in medical tourism, an increase in research activities in the region, the availability of sizable untapped markets, a sizable population pool, and the rising demand for high-quality healthcare in the region, Asia-Pacific is predicted to experience significant growth during the forecast period of 2023 to 2030.

Key Market Players

Bristol-Myers Squibb Company (Celgene Corporation)

Novartis AG

Genmab AS

Otsuka Holdings Co. Ltd

Sanofi-Aventis (Genzyme Corporation)

Teva Pharmaceutical (Cephalon Inc.)

Pfizer Inc.

F. Hoffmann-La Roche Ltd

Sunesis Pharmaceuticals Inc.

Astellas Pharma

Oncolyze Inc.

Syndax Pharmaceuticals Inc.

AbbVie Inc.

Amgen Inc.

Agios Pharmaceuticals Inc.

Report Scope:

In this report, the Global Acute Myeloid Leukemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Myeloid Leukemia Market, By Chemotherapy:

Cytarabine Anthracycline Drugs Alkylating Agents Anti-metabolites Tyrosine Kinase Inhibitors Hormonal therapy Other chemotherapies

Acute Myeloid Leukemia Market, By region:

North America
• United States
• Canada
• Mexico
Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Myeloid Leukemia Market.

Available Customizations:

Global Acute Myeloid Leukemia Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Acute Myeloid Leukemia Market

5. Voice of Customer

6. Global Acute Myeloid Leukemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, hormonal therapy, and other chemotherapies)
  • 6.2.2. By Region
  • 6.2.3. By Company (2023)
• 6.3. Market Map

7. Asia Pacific Acute Myeloid Leukemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Chemotherapy
  • 7.2.2. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Acute Myeloid Leukemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Chemotherapy
  • 7.3.2. India Acute Myeloid Leukemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Chemotherapy
  • 7.3.3. Australia Acute Myeloid Leukemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Chemotherapy
  • 7.3.4. Japan Acute Myeloid Leukemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Chemotherapy
  • 7.3.5. South Korea Acute Myeloid Leukemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Chemotherapy

8. Europe Acute Myeloid Leukemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Chemotherapy
  • 8.2.2. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Acute Myeloid Leukemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Chemotherapy
  • 8.3.2. Germany Acute Myeloid Leukemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Chemotherapy
  • 8.3.3. Spain Acute Myeloid Leukemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Chemotherapy
  • 8.3.4. Italy Acute Myeloid Leukemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Chemotherapy
  • 8.3.5. United Kingdom Acute Myeloid Leukemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Chemotherapy

9. North America Acute Myeloid Leukemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Chemotherapy
  • 9.2.2. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Acute Myeloid Leukemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Chemotherapy
  • 9.3.2. Mexico Acute Myeloid Leukemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Chemotherapy
  • 9.3.3. Canada Acute Myeloid Leukemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Chemotherapy

10. South America Acute Myeloid Leukemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Chemotherapy
  • 10.2.2. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Chemotherapy
  • 10.3.2. Argentina Acute Myeloid Leukemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Chemotherapy
  • 10.3.3. Colombia Acute Myeloid Leukemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Chemotherapy

11. Middle East and Africa Acute Myeloid Leukemia Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Chemotherapy
  • 11.2.2. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Acute Myeloid Leukemia Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Chemotherapy
  • 11.3.2. Saudi Arabia Acute Myeloid Leukemia Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Chemotherapy
  • 11.3.3. UAE Acute Myeloid Leukemia Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Chemotherapy

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Acute Myeloid Leukemia Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. Bristol-Myers Squibb Company (Celgene Corporation)
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (In case of listed companies)
  • 17.1.5. Recent Developments
  • 17.1.6. SWOT Analysis
• 17.2. Novartis AG
• 17.3. Genmab AS
• 17.4. Otsuka Holdings Co. Ltd
• 17.5. Sanofi-Aventis (Genzyme Corporation)
• 17.6. Teva Pharmaceutical (Cephalon Inc.)
• 17.7. Pfizer Inc.
• 17.8. F. Hoffmann-La Roche Ltd
• 17.9. Sunesis Pharmaceuticals Inc.
• 17.10. Astellas Pharma
• 17.11. Oncolyze Inc.
• 17.12. Syndax Pharmaceuticals Inc.
• 17.13. AbbVie Inc.
• 17.14. Amgen Inc.
• 17.15. Agios Pharmaceuticals Inc.

18. Strategic Recommendations

19. About Us & Disclaimer